Rheumatology Network's Top 5: April 2, 2021

April 2, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 2, 2021.

Juvenile Idiopathic Arthritis Linked to Greater Prevalence of Coexisting Autoimmune Diseases

Of the 26 autoimmune disease and related conditions studied, 14 (53.8%) had higher prevalence in the juvenile idiopathic arthritis (JIA) group when compared with the general pediatric (GP) population cohort.

Click the image to view the story.

Tofacitinib Does Not Increase Risk of Venous Thromboembolism in Patients With RA

Recently, a link between venous thromboembolism (VTE) and Janus Kinase (JAK) inhibitors has emerged, causing the FDA to recommend a black box label for tofacitinib in 2019. New research, however, suggests that tofacitinib had similarly infrequent cases of VTE (<1 per 100) when compared with tumor necrosis factor inhibitors (TNFIs).

Click the image to view the story.

Fatigue in Patients With Systemic Lupus Erythematosus Linked to Anxiety and Depression

While some patients with systemic lupus erythematosus (SLE) find it beneficial to receive anti-inflammatory therapy to treat their fatigue, there is increasingly more evidence that chronic diseases increase risk of psychiatric disorders, such as anxiety and depression, which need to be treated differently.

Click the image to view the story.

Recruitment Enhancement for Trials Aimed at Individuals At-Risk for Rheumatoid Arthritis

Investigators identified both facilitators and barriers for trial participation in patients at risk for rheumatoid arthritis (RA) in order to enhance inclusion in trials designed to prevent RA.

Click the image to view the story.

Survey Shows Positive Trends in Digital Health Applications During COVID-19 Pandemic

COVID-19 has created new challenges and opportunities in the way that rheumatologists care for chronically ill patients, including the introduction and prevalence of telemedicine and digital health applications (DHAs).

Click the image to view the story.